Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy

The objective of this study was to determine whether the expressions of the excision cross-complementing (ERCC1), thymidylate synthase (TS) and glutathione S-transferase P1 (GSTP1) are predictive of clinical outcomes in advanced gastric cancer (AGC) patients receiving treatment with adjuvant 5-fluorouracil (5-FU) and cisplatin (FP) chemotherapy. One hundred forty nine patients were included in this study. ERCC1 and GSTP1 expression was correlated significantly with tumor size (p = 0.040, p = 0.018, respectively). Stage and positive lymph node ratio were associated independently with disease free survival (DFS) and overall survival (OS). Both ERCC1 and GSTP1 expression had a significant impact on OS (hazard ratio = 0.069, p = 0.021). TS expression was not related to DFS and OS.

[1]  S. Tsuchida,et al.  Glutathione transferases and cancer. , 1992, Critical reviews in biochemistry and molecular biology.

[2]  A. Matakidou,et al.  Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Wolf,et al.  Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. , 1990, Carcinogenesis.

[4]  Eddie Reed.  ERCC1 and Clinical Resistance to Platinum-Based Therapy , 2005, Clinical Cancer Research.

[5]  M. Roh,et al.  Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  C. Wittmer,et al.  Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) – novel predictors for response and survival in gastric cancer patients , 2005, British Journal of Cancer.

[7]  G. Mann,et al.  Adjuvant therapy in gastric cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Hoeschele,et al.  Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. , 1980, Chemico-biological interactions.

[9]  S. Marsh,et al.  Cancer pharmacogenetics , 2004, British Journal of Cancer.

[10]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[11]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Lenz,et al.  Determinants of chemosensitivity in gastric cancer. , 2006, Current opinion in pharmacology.

[13]  Y. Hishikawa,et al.  Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. , 1997, Oncology.

[14]  J. Meyerhardt,et al.  Adjuvant and Neoadjuvant Approaches in Gastric Cancer , 2007, Cancer journal.

[15]  D. Harpole,et al.  The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Y. Shimada,et al.  Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer , 2008, British Journal of Cancer.

[17]  S. Im,et al.  Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival , 2009, British Journal of Cancer.

[18]  S. Groshen,et al.  ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Kohno,et al.  Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. , 1999, Free radical research.

[20]  Michael D. Wilson,et al.  ERCC1: A comparative genomic perspective , 2001, Environmental and molecular mutagenesis.

[21]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[22]  Elisabeth Brambilla,et al.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.

[23]  D. Roder,et al.  The epidemiology of gastric cancer , 2002, Gastric Cancer.

[24]  H. Wieand,et al.  Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. , 1989, Cancer research.

[25]  A. Yasui,et al.  Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10 , 1986, Cell.

[26]  Hai-rim Shin,et al.  Nationwide cancer incidence in Korea, 2003-2005. , 2009, Cancer research and treatment : official journal of Korean Cancer Association.

[27]  Jae Jin Lee,et al.  Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. , 2006, Cancer research and treatment : official journal of Korean Cancer Association.

[28]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[29]  J. Xiang,et al.  Meta‐analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer , 2009, The British journal of surgery.

[30]  M. Ychou,et al.  Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.